📰 James Basta News
James Basta News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from James Basta. Real-time updates on events, politics, business and more.
May 27, 2024
Contrarius Investment Management Ltd decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 214,401 shares of the company’s stock after selling 17,461 shares during the quarter. Contrarius Investment Management Ltd owned […]
April 30, 2024
Merlin Capital Inc raised its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 44.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 26,834 shares of the company’s stock after acquiring an additional 8,308 shares during the period. Intellia Therapeutics makes up 2.6% of Merlin Capital Inc’s investment portfolio, making the stock […]
April 30, 2024
Merlin Capital Inc lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 44.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,834 shares of the company’s stock after buying an additional 8,308 shares during the period. Intellia Therapeutics comprises […]
April 28, 2024
Jennison Associates LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 26.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,848 shares of the company’s stock after purchasing an additional 4,949 shares during the period. Jennison Associates LLC’s holdings in […]
April 28, 2024
Abrdn plc bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 154,269 shares of the company’s stock, valued at approximately $4,704,000. abrdn plc owned about 0.17% of Intellia Therapeutics as […]
April 27, 2024
Wedbush reiterated their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $29.00 target price on the stock. A number of other equities research analysts also recently weighed in on NTLA. Wolfe Research assumed coverage on Intellia Therapeutics in a […]
April 20, 2024
Resonant Capital Advisors LLC lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 32.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 41,348 shares of the company’s stock after buying an additional 10,082 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Intellia Therapeutics were worth $1,261,000 […]
April 12, 2024
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price […]
April 6, 2024
Chevy Chase Trust Holdings LLC decreased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 991,175 shares of the company’s stock after selling 11,780 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Intellia Therapeutics were worth $30,221,000 at the […]
April 5, 2024
China Universal Asset Management Co. Ltd. grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 357.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 10,355 shares of the company’s stock after acquiring an additional 8,092 shares during the quarter. China Universal […]